Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-679-5 | CAS number: 68-12-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well-documented publication (review) which meets basic scientific principles
Data source
Reference
- Reference Type:
- publication
- Title:
- Occupational Toxicants
- Author:
- Greim, H.
- Year:
- 1 992
- Bibliographic source:
- Critical Data Evaluation for MAK Values and Classification of Carcinogens, Vol.8
Materials and methods
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- - Principle of test: Comprehensive review of available results regarding ADME of the test substance DMF
- Short description of test conditions: Rats were administered DMF via oral, dermal and inhalation routes of exposure - GLP compliance:
- not specified
Test material
- Reference substance name:
- N,N-dimethylformamide
- EC Number:
- 200-679-5
- EC Name:
- N,N-dimethylformamide
- Cas Number:
- 68-12-2
- Molecular formula:
- C3H7NO
- IUPAC Name:
- N,N-dimethylformamide
- Details on test material:
- Name of test material: N,N-dimethylformamide
Constituent 1
- Radiolabelling:
- not specified
Test animals
- Species:
- rat
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- no details given
Administration / exposure
- Route of administration:
- other: oral, dermal, inhalation
- Vehicle:
- not specified
- Details on exposure:
- No information given
Results and discussion
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- N,N-dimethylformamide is readily absorbed after oral intake, dermal exposure or inhalation.
- Type:
- distribution
- Results:
- N,N-dimethylformamide is rapidly and uniformly distributed in the organism.
- Type:
- metabolism
- Results:
- Metabolization takes place mainly in the liver by microsomal enzymes.
Toxicokinetic / pharmacokinetic studies
- Details on excretion:
- The cysteine adduct N-acetyl-S-(N-methylcarbamoyl)cysteine is also found in urine at levels of 1 % to 5 % of the dose in urine of laboratory animals (mice, rat, hamsters) treated parenterally and at 10 % to 23 % of the dose in persons who had inhaled the substance. Formation and excretion of the cysteine adduct (N-acetyl-S-(N-methylcarbamoyl)cysteine) in the urine of persons inhaling N,N-dimethylformamide takes place with a half-time of 23 hours.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- N-hydroxymethyl-N-methylformamide is the main metabolite of N,N-dimethylformamide in animals and human beings and it is excreted with the urine. Mono-N-methylformamide which was once considered to be the main metabolite of N,N-dimethylformamide is found only in low levels in the urine. It could be shown that mono-N-methylformamide was mainly an artefact formed on the gas chromatographic column.
Any other information on results incl. tables
Moreover it was shown, that intermediary metabolism produces to a lower extent via a second pathway glutathione adducts and its degradation products. As carbamoylating species, which reacts with glutathione methyl isocyanate was postulated but not proven. Moreover, investigations in animals had shown that at least after administration in single high doses, N,N-dimethylformamide can inhibit its own metabolism (saturated metabolism). Metabolic interaction occurs between N,N-dimethylformamide and ethanol. Ethanol and probably the ethanol metabolite, acetaldehyde inhibit the breakdown of N,N-dimethylformamide. Conversely, N,N-dimethylformamide inhibits the metabolism of ethanol and acetaldehyde. Thus, increased N,N-dimethylformamide levels in the blood were found after the administration of alcohol and increased alcohol or acetaldehyde levels for up to 24 hours were reported after exposure to N,N-dimethylformamide.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results: no bioaccumulation potential based on study results
N,N-dimethylformamide is readily absorbed after oral intake, dermal exposure or inhalation. N,N-dimethylformamide is rapidly and uniformly distributed in the organism. Metabolization takes place mainly in the liver by microsomal enzymes. N-hydroxymethyl-N-methylformamide is the main metabolite of N,N-dimethylformamide in animals and human beings and it is excreted with the urine. Mono-N-methylformamide which was once considered to be the main metabolite of N,N-dimethylformamide is found only in low levels in the urine. It could be shown that mono-N-methylformamide was mainly an artefact formed on the gas chromatographic column. Another metabolite cysteine adduct (N-acetyl-S-(N-methylcarbamoyl)cysteine) is measured in the urine of persons inhaling N,N-dimethylformamide. - Executive summary:
Study design
This publication (review) provides an acceptable well-documented in vivo study (not according to OECD Test guideline) which meets basic scientific principles.
In this metabolism study, rats were administered N,N-dimethylformamide (DMF) via oral, dermal and inhalation routes of exposure.
Results
Metabolization took place mainly in the liver by microsomal enzymes. N-hydroxymethyl-N-methylformamide (DMF-OH or HMMF) was the main metabolite of DMF in animals and human beings and it is excreted with the urine. Mono-N-methylformamide (MMF) which was once considered to be the main metabolite of DMF was found only in low levels in the urine. It could be shown that MMF was mainly an artefact formed on the gas chromatographic column. Moreover it was shown, that intermediary metabolism produces to a lower extent via a second pathway glutathione adducts and its degradation products. As carbamoylating species, which reacts with glutathione methyl isocyanate was postulated but not proven. Moreover, investigations in animals had shown that at least after administration in single high doses, DMF can inhibit its own metabolism (saturated metabolism). Metabolic interaction occurs between DMF and ethanol. Ethanol and probably the ethanol metabolite, acetaldehyde inhibit the breakdown of N,N-dimethylformamide. Conversely, N,N-dimethylformamide inhibits the metabolism of ethanol and acetaldehyde. Thus, increased DMF levels in the blood were found after the administration of alcohol and increased alcohol or acetaldehyde levels for up to 24 hours were reported after exposure to N,N-dimethylformamide.
Conclusion
DMF was readily absorbed via all exposure routes and uniformly distributed throughout the organism.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
